Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Lipid mediator profiles predict response to therapy with an oral frankincense extract in relapsing-remitting multiple sclerosis

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB
[thumbnail of Supplemental Information]
Preview
PDF (Supplemental Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB

Item Type:Article
Title:Lipid mediator profiles predict response to therapy with an oral frankincense extract in relapsing-remitting multiple sclerosis
Creators Name:Stürner, K.H., Werz, O., Koeberle, A., Otto, M., Pless, O., Leypoldt, F., Paul, F. and Heesen, C.
Abstract:Lipid mediators (LMs) are a unique class of immunoregulatory signalling molecules and known to be affected by frankincense extracts. We performed LM profiling by metabololipidomics in plasma samples from 28 relapsing-remitting multiple sclerosis (RR-MS) patients who took a standardised frankincense extract (SFE) daily for eight months in a clinical phase IIa trial (NCT01450124) and in 28 age- and gender-matched healthy controls. Magnetic resonance imaging, immunological outcomes and serum neurofilament light chain levels were correlated to changes in the LM profiles of the RR-MS cohort. Eight out of 44 analysed LMs were significantly reduced during an eight-month treatment period by the SFE and seven of these eight significant LM derive from the 5-lipoxygenase (5-LO) pathway. Baseline levels of 12- and 15-LO products were elevated in patients who exhibited disease activity (EDA) during SFE treatment compared to no-evidence-of-disease-activity (NEDA) patients and could predict treatment response to the SFE in a prediction model at baseline. Oral treatment with an SFE significantly reduces 5-LO-derived LMs in RR-MS patients during an eight-month treatment period. Treatment response to an SFE, however, seems to be related to 12-,15-LO and cyclooxygenase product levels before SFE exposure. Further studies should confirm their biomarker potential in RR-MS and SFE treatment.
Keywords:Biomarkers, Case-Control Studies, Electrospray Ionization Mass Spectrometry, Frankincense, Lipidomics, Lipids, Neurofilament Proteins, Oral Administration, Relapsing-Remitting Multiple Sclerosis, Unsaturated Fatty Acids
Source:Scientific Reports
ISSN:2045-2322
Publisher:Nature Publishing Group
Volume:10
Number:1
Page Range:8776
Date:29 May 2020
Official Publication:https://doi.org/10.1038/s41598-020-65215-6
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library